Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Brettschneider, Johannes ^a,b   Toledo, Jon B ^a   van Deerlin, Vivianna M ^a   Elman, Lauren ^a   McCluskey, Leo ^a   Lee, Virginia M Y ^a   Trojanowski, John Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD68 ANTIBODY; MYELIN; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOPSY; BRAIN REGION; CELL ACTIVATION; CELL LOSS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENE LOSS; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MEDULLA OBLONGATA; MICROGLIA; MOTOR CORTEX; MOTOR NEURON DISEASE; NERVE FIBER; NEUROPATHOLOGY;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; AXONS; BASE SEQUENCE; COHORT STUDIES; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; HUMANS; MALE; MICROGLIA; MIDDLE AGED; MOTOR NEURONS; OPEN READING FRAMES; POLYMERASE CHAIN REACTION;

EID: 84862245802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039216     Document Type: Article

References (68)

1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, et al. (2011) Amyotrophic lateral sclerosis. Lancet 377: 942-955.
2. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133.
3. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, et al. (1993) Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261: 1047-1051.
4. Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, et al. (2004) Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 89: 464-473.
5. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615-622.
6. Troakes C, Maekawa S, Wijesekera L, Rogelj B, Siklos L, et al. (2011) An MND/ALS phenotype associated with C9orf72 repeat expansion: Abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neuropathology.
7. Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, et al. (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11: 54-65.
8. Bigio EH, (2011) C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. Acta Neuropathol 122: 653-655.
9. Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, et al. (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 122: 691-702.
10. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268.
11. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245-256.
12. Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cashman N, et al. (2012) Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol.
13. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, et al. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 99: 1604-1609.
14. Van Damme P, Bogaert E, Dewil M, Hersmus N, Kiraly D, et al. (2007) Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A 104: 14825-14830.
15. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW, (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73-84.
16. Pena EA, Slate EH, (2006) Global Validation of Linear Model Assumptions. J Am Stat Assoc 101: 341.
17. Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, et al. (2011) Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 122: 657-671.
18. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN, (2000) Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 123 (Pt 11): 2289-2296.
19. Henkel JS, Beers DR, Zhao W, Appel SH, (2009) Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 4: 389-398.
20. Brettschneider J, Libon DJ, Toledo JB, Xie SX, McCluskey L, et al. (2012) Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol.
21. Kriz J, Nguyen MD, Julien JP, (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268-278.
22. McGeer PL, McGeer EG, (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26: 459-470.
23. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
24. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52: 771-778.
25. Zhu X, Hill RA, Nishiyama A, (2008) NG2 cells generate oligodendrocytes and gray matter astrocytes in the spinal cord. Neuron Glia Biol 4: 19-26.
26. Mosley RL, Gendelman HE, (2010) Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol 222: 1-5.
27. McGeer EG, McGeer PL, (2005) Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 19: 31-37.
28. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, et al. (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15: 601-609.
29. Brooks BR, Miller RG, Swash M, Munsat TL, (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 293-299.
30. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, et al. (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169: 13-21.
31. Kleyweg RP, van der Meche FG, Schmitz PI, (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14: 1103-1109.
32. Bohannon RW, Smith MB, (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67: 206-207.
33. Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, et al. (1999) Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 53: 1051-1058.
34. Smith RA, Berg JE, Pope LE, Thisted RA, (2004) Measuring pseudobulbar affect in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 5: 99-102.
35. Geser F, Lee VM, Trojanowski JQ, (2010) Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 30: 103-112.
36. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, et al. (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66: 180-189.
37. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, et al. (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117: 137-149.
38. Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, et al. (2010) Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 67: 1238-1250.
39. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, et al. (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67: 555-564.
40. Hickey WF, Lee V, Trojanowski JQ, McMillan LJ, McKearn TJ, et al. (1983) Immunohistochemical application of monoclonal antibodies against myelin basic protein and neurofilament triple protein subunits: advantages over antisera and technical limitations. J Histochem Cytochem 31: 1126-1135.
41. Itoh T, Sobue G, Ken E, Mitsuma T, Takahashi A, et al. (1992) Phosphorylated high molecular weight neurofilament protein in the peripheral motor, sensory and sympathetic neuronal perikarya: system-dependent normal variations and changes in amyotrophic lateral sclerosis and multiple system atrophy. Acta Neuropathol 83: 240-245.
42. Sobue G, Hashizume Y, Yasuda T, Mukai E, Kumagai T, et al. (1990) Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. Acta Neuropathol 79: 402-408.
43. Schnell SA, Staines WA, Wessendorf MW, (1999) Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 47: 719-730.
44. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H, (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66: 852-856.
45. Holness CL, Simmons DL, (1993) Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81: 1607-1613.
46. Fambrough DM, Takeyasu K, Lippincott-Schwarz J, Siegel NR, (1988) Structure of LEP100, a glycoprotein that shuttles between lysosomes and the plasma membrane, deduced from the nucleotide sequence of the encoding cDNA. J Cell Biol 106: 61-67.
47. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, et al. (2000) Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 19: 4439-4448.
48. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, et al. (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57: 1-9.
49. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S, (1996) A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224: 855-862.
50. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S, (2000) Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci 113 (Pt 17): 3073-3084.
51. Imai Y, Kohsaka S, (2002) Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia 40: 164-174.
52. Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, et al. (2007) Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 55: 687-700.
53. Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, et al. (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122: 673-690.
54. Ince PG, Evans J, Knopp M, Forster G, Hamdalla HH, et al. (2003) Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 60: 1252-1258.
55. Kawamata T, Akiyama H, Yamada T, McGeer PL, (1992) Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140: 691-707.
56. Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, et al. (2004) Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55: 221-235.
57. Alexianu ME, Kozovska M, Appel SH, (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57: 1282-1289.
58. Hall ED, Oostveen JA, Gurney ME, (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23: 249-256.
59. Weydt P, Yuen EC, Ransom BR, Moller T, (2004) Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48: 179-182.
60. Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, et al. (2007) Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem 102: 2008-2019.
61. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, et al. (2006) Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 103: 16021-16026.
62. Zhao W, Xie W, Xiao Q, Beers DR, Appel SH, (2006) Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem 99: 1176-1187.
63. Lasiene J, Yamanaka K, (2011) Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011: 718987.
64. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, et al. (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312: 1389-1392.
65. Wang L, Sharma K, Grisotti G, Roos RP, (2009) The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol Dis 35: 234-240.
66. Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, et al. (2009) Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem 284: 8516-8524.
67. Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ, (2000) Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging 21: 913-919.
68. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M, (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 5: e8784.